{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:56:31Z","timestamp":1788267391137,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cjca.2015.12.023","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T17:30:28Z","timestamp":1451323828000},"page":"852-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Vascular Complications of Cancer Chemotherapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Alan C.","family":"Cameron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M.","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.12.023_bib1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.12.023_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ncpcardio1375","article-title":"Vascular complications of selected cancer therapies","volume":"5","author":"Daher","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cjca.2014.04.029","article-title":"Chemotherapy-induced cardiotoxicity: detection, prevention, and management","volume":"30","author":"Truong","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.12.023_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcm.2014.07.003","article-title":"An update on cardio-oncology","volume":"24","author":"Herrmann","year":"2014","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cjca.2015.12.023_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J\u00a0Cardiol"},{"key":"10.1016\/j.cjca.2015.12.023_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4174\/astr.2015.89.1.1","article-title":"Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis","volume":"89","author":"Lee","year":"2015","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/febs.13545","article-title":"Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies","volume":"283","author":"Maes","year":"2016","journal-title":"FEBS"},{"key":"10.1016\/j.cjca.2015.12.023_bib10","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1167\/iovs15-16950","article-title":"VEGF receptor-2\u2013linked PI3K\/calpain\/SIRT1 activation mediates retinal arteriolar dilations to VEGF and shear stress","volume":"56","author":"Hein","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.cjca.2015.12.023_bib11","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/ATVBAHA.110.211581","article-title":"Nitric oxide synthase expression and functional response to nitric oxide are both important modulators of circulating angiogenic cell response to angiogenic stimuli","volume":"30","author":"Heiss","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2015.12.023_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCRESAHA.115.307408","article-title":"VEGF-induced expression of miR-17\u223c92 cluster in endothelial cells is mediated by ERK\/ELK1 activation and regulates angiogenesis","volume":"118","author":"Chamorro-Jorganes","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/02841860310001835","article-title":"Chemotherapy and antiangiogenesis","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0959-8049(00)00092-7","article-title":"\u201cAccidental\u201d anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples","volume":"36","author":"Kerbel","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.1986.4.9.1405","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"4","author":"Doll","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib16","first-page":"109","article-title":"A\u00a0mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization","volume":"43","author":"Yoshikawa","year":"1997","journal-title":"Kobe J\u00a0Med Sci"},{"key":"10.1016\/j.cjca.2015.12.023_bib17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.1989.7.8.1099","article-title":"Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin","volume":"7","author":"Stoter","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/ctrv.2000.0175","article-title":"Long-term chemotherapy-related cardiovascular morbidity","volume":"26","author":"Meinardi","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib20","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.12.023_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm0806-881","article-title":"Targeted cancer therapeutics: the heartbreak of success","volume":"12","author":"Mann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A\u00a0small molecule\u2013kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2015.12.023_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cjca.2015.12.023_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ctrv.2013.11.009","article-title":"Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents","volume":"40","author":"Limaverde-Sousa","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1634\/theoncologist.2010-0271","article-title":"Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review","volume":"16","author":"Keefe","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2015.12.023_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jch.12052","article-title":"Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors","volume":"15","author":"Caro","year":"2013","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.cjca.2015.12.023_bib28","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.12.023_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2014.08.004","article-title":"Hypertension induced by chemotherapeutic and immunosuppressive agents: a new challenge","volume":"93","author":"Abi Aad","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cjca.2015.12.023_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2015.12.023_bib31","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1152\/ajpregu.00373.2015","article-title":"Endothelin-1 and antiangiogenesis","volume":"310","author":"Lankhorst","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cjca.2015.12.023_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425255.2012.656845","article-title":"Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy","volume":"8","author":"Horsley","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cjca.2015.12.023_bib33","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2015.12.023_bib34","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2015.12.023_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2015.12.023_bib37","doi-asserted-by":"crossref","first-page":"1733.e1","DOI":"10.1016\/j.cjca.2014.08.023","article-title":"Hypertension due to antiangiogenic cancer therapy with VEGF inhibitors: is autonomic nervous system toxicity another possible mechanism?","volume":"30","author":"McIntyre","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.12.023_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000334458","article-title":"Antiangiogenic-induced hypertension: the molecular basis of signaling network","volume":"73","author":"Nagai","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.cjca.2015.12.023_bib39","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cjca.2015.12.023_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clcc.2011.03.021","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2015.12.023_bib43","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2015.12.023_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/157340311799960636","article-title":"Cardiotoxicity of molecularly targeted agents","volume":"7","author":"Hedhli","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib45","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"Kuenen","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2015.12.023_bib46","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib51","doi-asserted-by":"crossref","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2015.12.023_bib52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib53","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cjca.2015.12.023_bib55","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cjca.2015.12.023_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cjca.2015.12.023_bib57","first-page":"1","article-title":"Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib","volume":"1","author":"Kristensen","year":"2012","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.cjca.2015.12.023_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cjca.2015.12.023_bib59","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/annonc\/mdf058","article-title":"Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer","volume":"13","author":"Strumberg","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib61","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2006.05.7836","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer: are there implications for blood pressure management in patients receiving chemotherapy?","volume":"24","author":"Kohli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib62","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib63","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1200\/JCO.2005.02.176","article-title":"The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib64","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ejca.2003.11.026","article-title":"Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage","volume":"40","author":"De Vos","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-116-9-709","article-title":"Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer","volume":"116","author":"Gietema","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib67","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.2000.18.10.2169","article-title":"Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature","volume":"18","author":"Weijl","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib68","first-page":"1","article-title":"Role of vascular congestion in cisplatin-induced acute renal failure in the rat","volume":"7","author":"Luke","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2015.12.023_bib69","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mds527","article-title":"Early development of the metabolic syndrome after chemotherapy for testicular cancer","volume":"24","author":"de Haas","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib71","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","article-title":"Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study","volume":"33","author":"Fung","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13697137.2010.522278","article-title":"Impact of platinum-based chemotherapy on the progression of atherosclerosis","volume":"14","author":"Sekijima","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.cjca.2015.12.023_bib73","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10147-014-0779-y","article-title":"Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study","volume":"20","author":"Watanabe","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/bjc.1990.391","article-title":"Renal function related to different treatment modalities for malignant germ cell tumours","volume":"62","author":"Aass","year":"1990","journal-title":"Br J\u00a0Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies","volume":"650","author":"El-Awady","year":"2011","journal-title":"Eur J\u00a0Pharmacol"},{"key":"10.1016\/j.cjca.2015.12.023_bib77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cjca.2015.12.023_bib78","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.cjca.2015.12.023_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1445-5994.2009.02144.x","article-title":"Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina","volume":"40","author":"Stewart","year":"2010","journal-title":"Intern Med J"},{"key":"10.1016\/j.cjca.2015.12.023_bib80","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0002-9343(87)90465-7","article-title":"Prinzmetal\u2019s angina during 5-fluorouracil chemotherapy","volume":"82","author":"Kleiman","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib81","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib82","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oxfordjournals.annonc.a010723","article-title":"The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture","volume":"7","author":"Cwikiel","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.cjca.2015.12.023_bib84","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib85","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Sch\u00f6ber","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib86","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.12.023_bib87","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ancard.2006.02.005","article-title":"Preventing the cardiotoxic effects of anthracyclines. From basic concepts to clinical data","volume":"55","author":"Delemasure","year":"2006","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"10.1016\/j.cjca.2015.12.023_bib89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cjca.2015.12.023_bib90","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2015.12.023_bib91","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","article-title":"Antivascular actions of microtubule-binding drugs","volume":"15","author":"Schwartz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib92","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib93","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FJC.0b013e3181d263f7","article-title":"Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells","volume":"55","author":"Wood","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2015.12.023_bib94","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis","volume":"11","author":"Vacca","year":"2002","journal-title":"J\u00a0Hematother Stem Cell Res"},{"key":"10.1016\/j.cjca.2015.12.023_bib95","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.1997.00613.x","article-title":"The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication","volume":"43","author":"B\u00e9har","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2015.12.023_bib96","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.12.023_bib97","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15016943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15016943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T15:21:17Z","timestamp":1537111277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15016943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0828282X15016943"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.12.023","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular Complications of Cancer Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}